Loading company…
Semma Therapeutics, based in Cambridge, develops encapsulated cell therapies for diabetes, acquired by Vertex in 2019.
Founded in 2014 and headquartered in Cambridge, US, Semma Therapeutics develops cell-based therapies for diabetes, including encapsulated insulin-producing cells for type 1 diabetes. Vertex Pharmaceuticals Incorporated acquired the company for USD 950 mn, with the deal closing in the fourth quarter of 2019. Before the acquisition, Semma had completed five deals, the most recent on September 3, 2019.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in